Heini Kari

Heini Kari

Auto-generated profile, based on publicly available information

Heini Kari

Research Unit, The Social Insurance Institution of Finland (Kela), Helsinki, Finland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2018 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
HKHeini Kari
Heini Kari
HKHanna Kortejärvi
Hanna Kortejärvi
MAMarja Airaksinen
Marja Airaksinen
RLRaisa Laaksonen
Raisa Laaksonen

1 June 2022 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Open access
HKHeini Kari
Heini Kari
NÄNelli Äijö-Jensen
Nelli Äijö-Jensen
HKHanna Kortejärvi
Hanna Kortejärvi
JRJukka Ronkainen
Jukka Ronkainen
MYMarjo Yliperttula
Marjo Yliperttula
MBMarja Blom
Marja Blom
There is a need for effective and cost-effective interprofessional care models that support older people to maintain their quality of life (QoL) and physical performance to live longer independently in their own homes. The objectives were to evaluate effectiveness, QoL and physical performance, and cost-utility of a people-centred care model (PCCM), including the contribution of clinically trained pharmacists, compared with that of usual care in primary care. A randomised controlled trial (RCT) with a two-year follow-up was conducted. The participants were multimorbid community-living older people, aged ≥75 years. The intervention comprised an at-home patient interview, health review, pharmacist-led clinical medication review, an interprofessional team meeting, and nurse-led care coordination and health support. At the baseline and at the 1-year and 2-year follow-ups, QoL (SF-36, 36-Item Short-Form Health Survey) and physical performance (SPPB, Short Performance Physical Battery) were measured. Additionally, a physical dimension component summary in the SF-36 was calculated. The SF-36 data were transformed into SF-6D scores to calculate quality-adjusted life-years (QALYs). Healthcare resource use were collected and transformed into costs. A healthcare payer perspective was adopted. Incremental cost-effectiveness ratio (ICER) was calculated, and one-way sensitivity analysis was performed. No statistically or clinically significant differences were observed between the usual care (n = 126) and intervention group (n = 151) patients in their QoL; at the 2-year follow-up the mean difference was -0.02, (95 % CI -0.07; 0.04,p = 0.56). While the mean difference between the groups in physical performance at the 2-year follow-up was -1.02, (-1.94;-0.10,p = 0.03), between the physical component summary scores it was -7.3, (-15.2; 0.6,p = 0.07). The ICER was -73 638€/QALY, hence, the developed PCCM dominated usual care, since it was more effective and less costly. The cost-utility analysis showed that the PCCM including pharmacist-led medication review dominated usual care. However, it had no effect on QoL and the effect towards physical performance remained unclear.

18 December 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HKHeini Kari
Heini Kari
HRHanna Rättö
Hanna Rättö
LSLeena Saastamoinen
Leena Saastamoinen
HKHanna Koskinen
Hanna Koskinen
The COVID-19 pandemic has imposed an enormous burden on health care systems around the world. Simultaneously, many countries have reported a decrease in the incidence of other infectious diseases, such as acute respiratory infections, leading to a decline in outpatient antibiotic use. The aim of this study is to assess the impact of the COVID-19 pandemic on outpatient antibiotic prescribing in Finland during the first 2 years of the pandemic. We used nationwide register data, applied descriptive methods, and conducted an interrupted time series analysis (ITSA) using ARIMA modelling. Results from the ARIMA modelling showed that at the baseline, before the pandemic, the level of monthly number of antibiotic prescriptions was 248,560 (95% CI: 224,261 to 272,856; p<0.001) and there was a decreasing trend of 1,202 in monthly number of prescriptions (95% CI: -2,107 to -262; p<0.01). After the COVID-19 pandemic began, there was a statistically significant decline of 48,470 (95% CI: -76,404 to -20,535, p<0.001) prescriptions (-19.5% from the baseline level). The greatest decrease in antibiotic prescribing was observed among children aged 0–17 years. While antibiotic prescribing declined in all antibiotic groups associated with respiratory tract infections, the decrease from 2019 to 2020 was the largest with azithromycin (52.6%), amoxicillin (44.8%), and doxycycline (43.8%). Future studies should continue exploring antibiotic prescribing trends during the COVID-19 pandemic and beyond.

5 February 2022 in Exploratory Research in Clinical and Social Pharmacy
Verified
Journal Article
Open access
HKHeini Kari
Heini Kari
HKHanna Kortejärvi
Hanna Kortejärvi
RLRaisa Laaksonen
Raisa Laaksonen
Background: The ageing population with multiple conditions and complex health needs has forced healthcare systems to rethink the optimal way of delivering services. Instead of trying to manage numerous diseases in a siloed approach, the emphasis should be on people-centred practice, in which healthcare services are tailored to people's needs and provided in partnership with them. Objective: The aim was to develop an interprofessional people-centred care model (PCCM), including the contribution of a clinically trained pharmacist for home-living multimorbid older people in primary care. Methods: Participatory action research method, including the active involvement of healthcare professionals, was utilised to develop the PCCM in a public health centre in Finland. The data comprised interview transcripts, workshop materials, field notes, surveys, and memos and were analysed using inductive content analysis. Results: The PCCM was developed in iterative phases, including planning, acting, observing, and reflecting. The PCCM comprised: 1) A self-management evaluation questionnaire sent before a home visit; 2) A person-centred patient interview at home with a named nurse and a pharmacist; 3) A nurse-led health review and a pharmacist-led clinical medication review; 4) An interprofessional (a GP, a pharmacist and a named nurse) case conference meeting; 5) A care plan, including health and medication plans; and 6) Health support and empowerment interventions. The PCCM shifted working practices in the health centre from parallel and consultative practice towards interprofessional people-centred practice and more holistic care. The patient's active involvement in their own care was encouraged. Healthcare professionals appreciated the advantages of the new skill-mix, including the clinically trained pharmacist. Building trust among healthcare professionals and between the professionals and the patients was essential. Conclusion: The successfully developed PCCM improved holistic and more people-centred care in primary care. Healthcare professionals appreciated the advantages of the skill mix and found that trust was essential for implementing the PCCM.

15 November 2024 in Exploratory Research in Clinical and Social Pharmacy
Verified
Journal Article
Open access
HKHeini Kari
Heini Kari
FNFredriikka Nurminen
Fredriikka Nurminen
HRHanna Rättö
Hanna Rättö
HKHanna Koskinen
Hanna Koskinen
Medication non-adherence is associated with suboptimal health outcomes, higher mortality, and increased healthcare costs. The aim of this study was to estimate the number and share of non-dispensed prescriptions at a national level and in specific patient and medicine subgroups. The study was a nationwide retrospective register-based study. The data consisted of prescriptions prescribed in Finland in 2020 and dispensed between 2020 and 2022. A prescription was considered non-dispensed if it had not been dispensed within the two-year validity period. For each prescription, information on the patient's birth date, sex, and income as well as details of the prescribed medicine and physician's employment sector (public/private) were collected. Distributions and odds ratios (ORs) with corresponding 95 % confidence intervals (CI) were used in the analyses. Of the 26 million prescriptions, 13.3 % were never filled. Over 1.7 million people (43.3 % of all people with prescriptions issued in 2020) had at least one non-dispensed prescription. The share of non-dispensed prescriptions was lower in men than women (12.9 % vs. 13.5 %; OR:0.95; CI:0.95–0.95). Compared to the youngest age group, the share of non-dispensed prescriptions was lower in the older age groups. The lowest share of non-dispensed medicines was in antineoplastic and immunomodulating agents (7.8 %) and in cardiovascular system medicines (8.1 %), whereas the highest was in dermatologicals (20.2 %). The proportion of non-dispensed prescriptions varied between medicine groups, from 5 % for thyroid therapy to 38 % for other nervous system drugs. The most frequently non-dispensed medications were paracetamol, ibuprofen, and salbutamol. The share and number of non-dispensed prescriptions varied across therapeutic areas, medicine groups, active pharmaceutical ingredients, and patient groups. Healthcare professionals should avoid unnecessary prescribing and improve medication adherence to ensure safer and more effective care.

8 July 2025 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
PCPéter Csonka
Péter Csonka
FNFredriikka Nurminen
Fredriikka Nurminen
ELEero Lauhkonen
Eero Lauhkonen
HKHeini Kari
Heini Kari
Despite clear clinical guidelines advising against the use of cough and cold medicines (CCMs) in children, these products continue to be prescribed. We aimed at describing recent trends and identifying deviations from guidelines to inform future targeted interventions. We retrospectively retrieved data on all CCM prescriptions for children under 16 years of age in Finland between 2017 and 2023 from the centralised nationwide prescription registry. Descriptive statistical methods were used to analyse the data, stratified by child’s age, CCM type, physician’s employment sector, and medical specialty. The dataset included 96,499 prescriptions for 75,281 children. Overall, CCM prescribing decreased significantly from 2017 to 2023, particularly between 2017 and 2020, with the steepest decline in the 2–4.99-year age group. Prescribing levels did not return to pre-pandemic levels in any age group. Opium alkaloids and their derivatives were the most commonly prescribed CCMs for children under the age of 12. CCM prescribing rates were nearly identical across public and private sectors. Approximately 40% of prescriptions were issued by non-specialists and 18% by medical students—who constituted the largest group of public sector prescribers. In the private sector, the most frequent prescribers were paediatricians, non-specialists, general medicine specialists, and otolaryngologists. Conclusions: CCMs and especially opium alkaloids and their derivatives are still being prescribed even to small children. These findings should prompt nationwide multifaceted clinical guidance campaigns and interventions targeting medical students and non-specialist physicians, as well as private sector providers, including paediatricians and other specialists. What is known:• Despite guidelines advising against cough and cold medicines (CCMs) in children, prescribing persists. What is new:• CCM prescriptions for children declined markedly in Finland between 2017–2023, however opium alkaloids remained the most common among children under 12, despite CNS safety concerns. Non-specialists, general practitioners, and medical students prescribed CCMs most frequently. Specialist physicians were more likely to prescribe CCMs in the private sector, while the public sector had a broader mix of prescribers.